# Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer

> **NCT07733024** · PHASE2 · RECRUITING · sponsor: **Tingting Yuan** · enrollment: 200 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 68Ga-PFD3

## Key facts

- **NCT ID:** NCT07733024
- **Lead sponsor:** Tingting Yuan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733024, "Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*